BCM
TRIB

Breithorn Capital Management’s Trinity Biotech TRIB Stock Holding History

Breithorn Capital Management’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-1,001
Closed -$1.98M – 45
2016
Q3 		$1.98M Buy
1,001
+794
+384% +$1.48M 1.49% 28
2016
Q2 		$353K Buy
+207
New +$350K 0.27% 38

Other funds holding TRIB

PIM
Paradice Investment Management Denver, Colorado $627M AUM 43.41% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $2.25B AUM 44.61% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
LAM
Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $486M AUM 50.29% 1-Year Est. Return
SCM
Stonehill Capital Management New York $350M AUM 73.6% 1-Year Est. Return
2L
22NW LP Seattle, Washington $105M AUM 38.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SM
Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return

Breithorn Capital Management's TRIB Position: Q4 2016 in Review

Breithorn Capital Management sold out of Trinity Biotech (TRIB) in Q4 2016, closing a stake of 1,001 shares — an estimated $1.98M sold.

Breithorn Capital Management first reported a position in TRIB in Q2 2016 and held it in 2 quarters. The position peaked at $1.98M in Q3 2016. 71 funds tracked by Wall St. Rank hold TRIB as of Q4 2016.

  • Breithorn Capital Management reported no remaining Trinity Biotech position as of Q4 2016 after selling out during the quarter.
  • Breithorn Capital Management sold 1,001 Trinity Biotech shares in Q4 2016, an estimated $1.98M.
  • Breithorn Capital Management first reported a position in Trinity Biotech in Q2 2016 and held it in 2 quarters.
  • Breithorn Capital Management's Trinity Biotech position peaked at $1.98M in Q3 2016.
  • 71 funds tracked by Wall St. Rank held Trinity Biotech as of Q4 2016.

Based on Breithorn Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.